These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

609 related items for PubMed ID: 24908630

  • 1. The PD-1/PD-Ls pathway and autoimmune diseases.
    Dai S, Jia R, Zhang X, Fang Q, Huang L.
    Cell Immunol; 2014 Jul; 290(1):72-9. PubMed ID: 24908630
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. PD-1/PD-Ls pathways between CD4(+) T cells and pleural mesothelial cells in human tuberculous pleurisy.
    Yin W, Tong ZH, Cui A, Zhang JC, Ye ZJ, Yuan ML, Zhou Q, Shi HZ.
    Tuberculosis (Edinb); 2014 Mar; 94(2):131-9. PubMed ID: 24406080
    [Abstract] [Full Text] [Related]

  • 4. Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice.
    Yadav D, Hill N, Yagita H, Azuma M, Sarvetnick N.
    Cell Immunol; 2009 Mar; 258(2):161-71. PubMed ID: 19497561
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Biochemical signaling of PD-1 on T cells and its functional implications.
    Boussiotis VA, Chatterjee P, Li L.
    Cancer J; 2014 Mar; 20(4):265-71. PubMed ID: 25098287
    [Abstract] [Full Text] [Related]

  • 8. PD-1/PD-L pathway and autoimmunity.
    Okazaki T, Wang J.
    Autoimmunity; 2005 Aug; 38(5):353-7. PubMed ID: 16227150
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antibodies against B7-DC with differential binding properties exert opposite effects.
    Ritprajak P, Hashiguchi M, Akiba H, Yagita H, Okumura K, Azuma M.
    Hybridoma (Larchmt); 2012 Feb; 31(1):40-7. PubMed ID: 22316484
    [Abstract] [Full Text] [Related]

  • 12. Overexpression of programmed death ligand 1 in dendritic cells inhibits allogeneic lymphocyte activation in mice.
    Li W, Wang X, Chen R, Zhu H, Chen G, Sun X.
    J Surg Res; 2012 Aug; 176(2):e79-87. PubMed ID: 22381170
    [Abstract] [Full Text] [Related]

  • 13. B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway.
    Herold M, Posevitz V, Chudyka D, Hucke S, Groß C, Kurth F, Leder C, Loser K, Kurts C, Knolle P, Klotz L, Wiendl H.
    J Immunol; 2015 Oct 15; 195(8):3584-95. PubMed ID: 26378076
    [Abstract] [Full Text] [Related]

  • 14. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade.
    Pauken KE, Nelson CE, Martinov T, Spanier JA, Heffernan JR, Sahli NL, Quarnstrom CF, Osum KC, Schenkel JM, Jenkins MK, Blazar BR, Vezys V, Fife BT.
    J Immunol; 2015 Apr 15; 194(8):3551-3555. PubMed ID: 25769925
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.
    Carreno BM, Collins M.
    Annu Rev Immunol; 2002 Apr 15; 20():29-53. PubMed ID: 11861596
    [Abstract] [Full Text] [Related]

  • 19. Cellular and molecular regulation of the programmed death-1/programmed death ligand system and its role in multiple sclerosis and other autoimmune diseases.
    Ibañez-Vega J, Vilchez C, Jimenez K, Guevara C, Burgos PI, Naves R.
    J Autoimmun; 2021 Sep 15; 123():102702. PubMed ID: 34311143
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.